Towards a safe, effective vaccine for Rift Valley fever virus

Future Virology

Volumn 5, Issue 6, 2010, Pages 675-678

  LaBeaud, Desiree ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

Rift Valley Fever; vaccine

Indexed keywords

COMPLEMENT COMPONENT C3D; NEUTRALIZING ANTIBODY; PLASMID DNA; VIRUS VACCINE;

ALPHA VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; COUPLING FACTOR; FEMALE; HUMORAL IMMUNITY; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RIFT VALLEY FEVER; RIFT VALLEY FEVER BUNYAVIRUS; VACCINATION; VIRUS REPLICATION;

ALPHAVIRUS; ANIMALIA; MUS; RIFT VALLEY FEVER VIRUS;

EID: 78650060552     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.63     Document Type: Article

References (6)

1. Bhardwaj N, Heise MT, Ross TM: Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing Gn protects mice against Rift Valley Fever virus. PLoS Negl. Trop. Dis. 4(6), E725 (2010).
2. Won S, Ikegami T, Peters CJ, Makino S: NSm and 78-kilodalton proteins of Rift Valley Fever virus are nonessential for viral replication in cell culture. J. Virol. 80(16), 8274-8278 (2006).
3. Isaacson M: Viral hemorrhagic fever hazards for travelers in Africa. Clin. Infect. Dis. 33(10), 1707-1712 (2001).
4. CDC. Outbreak of Rift Valley Fever-Yemen, August-October 2000. MMWR 49 (47), 1065-1066 (2000).
5. Woods C W, Karpati AM, Grein T et al.: An outbreak of Rift Valley Fever in Northeastern Kenya, 1997-1998. Emerg. Infect. Dis. 8(2), 138-144 (2002).
6. Spik K, Shurtleff A, McElroy AK, Guttieri MC, Hooper JW, Schmaljohn C: Immunogenicity of combination DNA vaccines for Rift Valley Fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 24(21), 4657-4666 (2006).